<DOC>
	<DOCNO>NCT01833832</DOCNO>
	<brief_summary>Background : - Adrenocortical carcinoma ( ACC ) rare tumor adrenal gland . Few people develop disease live 5 year diagnose . Those whose tumor spread inside abdomen may especially poor outcome . In case , traditional chemotherapy effective . One possible new treatment aggressive surgery heat chemotherapy . This type treatment effective type cancer abdomen . Researchers want see approach improve outcome people ACC . Objectives : - To test safety effectiveness surgery heat chemotherapy ACC . Eligibility : - Individuals least 18 year age advance ACC . Design : - Participants screen physical exam medical history . Blood sample collect . Heart function test give . Imaging study use locate surgical site operation . - Participants surgery remove ACC tumor tissue . After tumor remove , heat chemotherapy cisplatin . The heat may help weaken remain cancer cell make easy destroy . It also focus treatment tumor site , rather whole body . - Participants recover hospital several day surgery . They regular follow-up visit monitor outcome surgery .</brief_summary>
	<brief_title>Surgery Heated Chemotherapy Adrenocortical Carcinoma</brief_title>
	<detailed_description>Background : - Adrenocortical carcinoma ( ACC ) rare tumor incidence 1.5 2 per million people per year poor prognosis overall 5-year mortality rate 75 - 90 % average survival time diagnosis 14.5 month . - The treatment choice localize primary recurrent tumor surgical resection . For unresectable metastatic recurrent disease , mitotane , aminoglutethimide , metapyrone , ketoconazole use . - Cisplatin one effective chemotherapeutic agent ACC . In Surgery Branch conduct Phase I II trial use heat intraperitoneal ( IP ) chemotherapy cisplatin primary peritoneal mesothelioma , low grade appendiceal adenocarcinoma , ovarian malignancy , high grade adenocarcinoma gastrointestinal tract . Synergy demonstrate cisplatin hyperthermia - The purpose trial determine aggressive surgical approach intraperitoneal administration heat cisplatin tumor volume minimal , impact improve progression free survival . Objectives : - To determine IP progression free survival optimal debulking heat IP chemotherapy cisplatin patient IP spread adrenocortical cancer Eligibility : - Histologically proven ACC evalauable CT image majority disease confine peritoneal cavity surgically resectable residual size le 1 cm amenable radiofrequency ablation patient &gt; 18 year age . Design : - This classic phase 2 trial determine efficacy therapeutic strategy ACC . Patients undergo cytoreductive surgery achieve CCR 0 1 . Patients successfully debulked undergo HIPEC cisplatin . Patients evaluated associate investigator coordination Principal Investigator eligibility . Due exploratory nature , 30 patient may enrol obtain 24 evaluable patient . ( Patients must undergo successful debulking HIPEC consider evaluable . )</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adrenocortical Carcinoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Sodium thiosulfate</mesh_term>
	<criteria>INCLUSION CRITERIA Histologically proven ACC majority disease confine peritoneal cavity resectable amenable radiofrequency ablation Disease evaluable CT PET image All disease deem resectable base image study e.g . : Hepatic metastasis ( unilateral bilateral less equal 5 lesion , less equal 15 cm total diameter ) Note : Hepatic lesion must amenable complete resection Primary peritoneal metastasis ( small disease load less equal P2 disease ) without massive ascites intestinal obstruction Lung metastases ( less equal 3 unilateral/bilateral , 9 cm total diameter ) Note : lung lesion must amenable complete resection Note : Patients pulmonary hepatic metastasis enrol discretion PI Note : In situation resection Completeness Cytoreduction Score ( CC ) 0 1 uncertain , patient may undergo diagnostic laparoscopy prior enrollment determine feasibility resection . Greater equal 18 year age Able understand sign Informed Consent Document Clinical performance status ECOG le equal 2 Life expectancy great three month Patients gender must willing practice birth control four month receive chemotherapy Hematology : Absolute neutrophil count great 1500/mm^3 without support Filgrastim . Platelet count great 75,000/mm^3 . Hemoglobin great 8.0 g/dl . Chemistry : Serum creatinine less equal 1.5 mg/dl unless measure creatinine clearance great 60 mL/min/1.73 m2 serum AST ALT within 5 time upper limit normal total serum bilirubin le 3 time upper limit normal , define upper limit grade 2 treatment related toxicity . PT within 2 second upper limit normal ( INR le equal 1.8 ) Recovered toxicity grade 2 less prior chemotherapy , immunotherapy radiotherapy least 30 day past date last treatment exception mitotane may continue . Able understand disease exploratory nature combine surgery HIPEC histology . EXCLUSION CRITERIA Concomitant medical problem would place patient unacceptable risk major surgical procedure . History congestive heart failure and/or LVEF le 40 % Note : Patients increase risk coronary artery disease cardiac dysfunction ( e.g. , great 65yo , diabetes , history hypertension , elevate LDL , first degree relative coronary artery disease ) undergo full cardiac evaluation eligible demonstrate significant irreversible ischemia stress thallium ejection fraction le 40 % . Significant COPD chronic pulmonary restrictive disease PFT indicate FEV1 le 50 % DLCO le 40 % predicted age Note : Patients shortness breath minimal exertion risk pulmonary disease ( e.g. , chronic smoker ) undergo pulmonary function test eligible FEV1 le 50 % expect . Grade 2 great neuropathy Women childbearing potential pregnant breastfeed potentially dangerous effect chemotherapy fetus infant . Brain metastasis history brain metastasis Childs B C cirrhosis Evidence severe portal hypertension history , endoscopy , radiologic study Note : Any diagnosis portal hypertension clinical stigma include limited gastric esophageal varix , umbilical vein varix telangectasias . Weight le 30 kg Active systemic infection , coagulation disorder major medical illness cardiovascular , respiratory immune system , myocardial infarction , cardiac arrhythmia , obstructive restrictive pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 24, 2017</verification_date>
	<keyword>Synergy Cisplatin Hyperthermia</keyword>
	<keyword>Rare Tumor</keyword>
	<keyword>Poor Prognosis</keyword>
</DOC>